<DOC>
	<DOC>NCT03088280</DOC>
	<brief_summary>Single-center, prospective, randomized, open-label clinical trial to evaluate the 1-year efficacy and safety of rATG 3mg/kg compared to 6mg/kg in low to moderate immunological risk patients receiving low exposure tacrolimus plus everolimus (EVL) in a steroid-free protocol.</brief_summary>
	<brief_title>Efficacy and Safety of Rabbit Antithymocyte Globulin 3mg/kg in Kidney Transplant Patients Under Steroid-free and CNI Minimization Maintenance Immunosuppressive Regimen</brief_title>
	<detailed_description />
	<mesh_term>Immunosuppressive Agents</mesh_term>
	<mesh_term>Antilymphocyte Serum</mesh_term>
	<criteria>Primary kidney transplant recipients, adults PRA &gt; 50% DSA &gt; 1500 MFI Retransplantation Patients who are planning to receive mycophenolate instead of everolimus Patients who have planning for followup in another center</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>March 2017</verification_date>
</DOC>